Ask AI
ProCE Banner Activity

Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Podcast Episodes

Listen to this conversation between Cristina Saura Manich, MD, PhD, and Giampaolo Bianchini, MD, as they discuss practical approaches to PI3K pathway testing, emerging PI3K and AKT-targeted treatment options, and sequencing therapy for patients with metastatic breast cancer following development of endocrine therapy resistance.

Released: June 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals caring for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the rationale for using PI3K/AKT/mTOR pathway inhibitors in HR+/HER2- metastatic breast cancer, including their mechanisms of action and clinical relevance in biomarker-selected populations

  • Develop individualized treatment plans based on biomarker testing, the latest clinical data, and patient-specific factors for patients with HR+/HER2- PIK3CA-mutated mBC

  • Identify patients eligible for PI3Ki therapy through appropriate biomarker testing and assessment of clinical risk factors, including those for treatment-induced hyperglycemia

  • Apply practical, evidence-based strategies for mitigating and managing treatment-related hyperglycemia to optimize adherence and outcomes

Financial Disclosures

Primary Author

Giampaolo Bianchini, MD: consultant/advisor/speaker: AstraZeneca, Amgen, Daiichi Sankyo, Exact Science, Gilead, Helsinn, Lilly, Menarini, MSD, Novartis, Pfizer, Roche, Seagen, Takeda, Tethis; researcher (paid to institution): Gilead.

Cristina Saura Manich, MD, PhD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, F. Hoffmann-La Roche, Gilead, Lilly, Novartis, Pfizer, Puma.